The Lancet Oncology in conversation with
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
Episodes
203 episodes
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-ce...
•
15:07
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.Read the full Article:
•
17:21
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Austra...
•
40:45
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY...
•
13:22
Emmy Boerrigter on dose selection of novel anticancer drugs
Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.Read the full article:
•
11:41
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations
Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and cli...
•
36:56
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment
Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and...
•
24:08
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean
Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American...
•
35:05
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Read the fu...
•
11:22
Maria Kyrgiou on innovations in gynaecological cancers and global disparities
In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.
•
25:42
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers
Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and ...
•
34:43
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a m...
•
16:06
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma
Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body r...
•
13:53
Neerja Bhatla on a new quadrivalent HPV vaccine
Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HP...
•
12:24
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery
Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldw...
•
43:49
Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma
Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intr...
•
17:10
Wanda Cui on measuring ovarian toxicity
Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.Read the full article:
•
10:37
Ticiana Leal on Tumour Treating Fields
Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.Read the full article:
•
9:01
Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA
Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.Read the full article:
•
12:31
Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma
Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.
•
33:50
Madeline Pe on the SISAQOL initiative
Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinic...
•
14:01
Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children
Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mi...
•
28:40
Mark Lythgoe on UK oncology drug approval after Brexit
Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".
•
14:11